PE20231385A1 - Composiciones de vacunas multivalentes y usos de las mismas - Google Patents
Composiciones de vacunas multivalentes y usos de las mismasInfo
- Publication number
- PE20231385A1 PE20231385A1 PE2023001175A PE2023001175A PE20231385A1 PE 20231385 A1 PE20231385 A1 PE 20231385A1 PE 2023001175 A PE2023001175 A PE 2023001175A PE 2023001175 A PE2023001175 A PE 2023001175A PE 20231385 A1 PE20231385 A1 PE 20231385A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- infections
- coli
- expec
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 150000004676 glycans Chemical class 0.000 abstract 4
- 229920001282 polysaccharide Polymers 0.000 abstract 4
- 239000005017 polysaccharide Substances 0.000 abstract 4
- 241000588724 Escherichia coli Species 0.000 abstract 3
- 208000019206 urinary tract infection Diseases 0.000 abstract 2
- 206010056519 Abdominal infection Diseases 0.000 abstract 1
- 206010007882 Cellulitis Diseases 0.000 abstract 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 abstract 1
- 206010058780 Meningitis neonatal Diseases 0.000 abstract 1
- 206010031252 Osteomyelitis Diseases 0.000 abstract 1
- 206010058674 Pelvic Infection Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000031650 Surgical Wound Infection Diseases 0.000 abstract 1
- 206010048038 Wound infection Diseases 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Esta referida a una composicion que comprende polisacaridos de antigeno O1, O2, O4, O15, O16, O18, O25, O75 y O6 de E. coli, en donde cada uno de los polisacaridos de antigeno esta unido independientemente de manera covalente a una proteina portadora, y en donde la concentracion de cada polisacarido de antigeno O75 y O25 aumenta independientemente con respecto a la concentracion de cada uno de los polisacaridos de antigeno O1, O2, O4, O15, O16, O18 y O6. La vacunacion con una composicion que contiene conjugados del antigeno O75 de E. coli y conjugados de uno o mas antigenos O adicionales de E. coli a una dosis y proporcion adecuadas proporciona una respuesta inmunitaria mejorada contra el serotipo O75 de ExPEC y los uno o mas serotipos O adicionales de ExPEC. Las cepas ExPEC son la causa mas comun de infeccion de las vias urinarias (IVU). Tambien contribuyen a las infecciones del sitio quirurgico y a la meningitis neonatal, asociadas con las infecciones abdominales y pelvicas y a la neumonia nosocomial, y ocasionalmente participan en otras infecciones extraintestinales como la osteomielitis, la celulitis y las infecciones de heridas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079734P | 2020-09-17 | 2020-09-17 | |
| EP21154782 | 2021-02-02 | ||
| US202163191471P | 2021-05-21 | 2021-05-21 | |
| PCT/IB2021/058485 WO2022058945A1 (en) | 2020-09-17 | 2021-09-17 | Multivalent vaccine compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231385A1 true PE20231385A1 (es) | 2023-09-12 |
Family
ID=77801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001175A PE20231385A1 (es) | 2020-09-17 | 2021-09-17 | Composiciones de vacunas multivalentes y usos de las mismas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220088165A1 (es) |
| EP (1) | EP4213870A1 (es) |
| JP (2) | JP7481585B2 (es) |
| KR (1) | KR20230043157A (es) |
| CN (1) | CN115803087A (es) |
| AU (1) | AU2021342797B2 (es) |
| BR (1) | BR112023004819A2 (es) |
| CA (1) | CA3190820A1 (es) |
| CL (1) | CL2023000740A1 (es) |
| CO (1) | CO2023002114A2 (es) |
| EC (1) | ECSP23019295A (es) |
| IL (2) | IL301248B2 (es) |
| MX (1) | MX2023003169A (es) |
| PE (1) | PE20231385A1 (es) |
| TW (1) | TW202227128A (es) |
| UY (1) | UY39428A (es) |
| WO (1) | WO2022058945A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210522A (es) | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
| WO2024107729A2 (en) * | 2022-11-15 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| WO2024146325A1 (zh) * | 2023-01-06 | 2024-07-11 | 中国人民解放军军事科学院军事医学研究院 | 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用 |
| GB202302579D0 (en) * | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2024186262A1 (en) * | 2023-03-03 | 2024-09-12 | Agency For Science, Technology And Research | Use of o-antigens for treating bacterial infections |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE69333107T2 (de) | 1992-02-11 | 2004-01-29 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
| PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
| ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
| ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| EP0814833B1 (en) | 1995-03-22 | 2003-05-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| KR100603884B1 (ko) | 1997-04-01 | 2006-07-24 | 코리사 코퍼레이션 | 모노포스포릴 지질 ａ의 수성 면역적 아쥬반트 조성물 |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| EP1588714A2 (en) | 1998-10-16 | 2005-10-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
| ES2309064T3 (es) | 2000-04-13 | 2008-12-16 | Corixa Corporation | Composiciones inmunoestimulantes que comprenden un fosfato de aminoalquil glucosaminida y qs-21. |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| IL163806A0 (en) | 2002-03-07 | 2005-12-18 | Eidgenoess Tech Hochschule | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| ATE483027T1 (de) | 2005-05-11 | 2010-10-15 | Eth Zuerich | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| WO2009089396A2 (en) | 2008-01-08 | 2009-07-16 | Neose Technologies, Inc. | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| KR20100123730A (ko) | 2008-02-20 | 2010-11-24 | 글리코박신 아게 | 원핵생물 세포로부터의 ｎ-당화된 재조합 단백질로부터 제조된 바이오컨쥬게이트 |
| SI2437753T1 (sl) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo |
| NZ704490A (en) | 2012-08-16 | 2017-07-28 | Pfizer | Glycoconjugation processes and compositions |
| JP2015529214A (ja) | 2012-09-10 | 2015-10-05 | グリコヴァキシン アーゲー | 修飾された抗原を含むバイオコンジュゲート及びその使用 |
| SG10201800777PA (en) | 2012-10-12 | 2018-02-27 | Glycovaxyn Ag | Methods of host cell modification |
| IL274500B2 (en) | 2012-12-20 | 2024-01-01 | Pfizer | glycoconjugation process |
| BR112015028341A2 (pt) | 2013-05-18 | 2017-07-25 | Aduro Biotech Inc | composições e métedos para ativação de "sinalização dependente de estimulador de gene interferon |
| CN103495161B (zh) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
| US11220676B2 (en) | 2013-10-11 | 2022-01-11 | Glaxosmithkline Biological Sa | Methods of host cell modification |
| EA201690859A1 (ru) | 2013-12-04 | 2016-11-30 | Гликоваксин Аг | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli |
| KR101855142B1 (ko) * | 2014-02-24 | 2018-05-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 신규한 폴리사카라이드 및 이의 용도 |
| PT3131577T (pt) | 2014-04-17 | 2020-07-17 | Glaxosmithkline Biologicals Sa | Células hospedeiras modificadas e suas utilizações |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| HUE057726T2 (hu) | 2014-12-30 | 2022-06-28 | Glaxosmithkline Biologicals Sa | Fehérje glikozilálására szolgáló készítmények és módszerek |
| TWI715617B (zh) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| US11260119B2 (en) * | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN113227125A (zh) | 2018-12-12 | 2021-08-06 | 葛兰素史密丝克莱恩生物有限公司 | 用于o-连接的糖基化的修饰的载体蛋白 |
| CR20210522A (es) * | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| AR118389A1 (es) * | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
| UY39710A (es) * | 2021-04-01 | 2022-09-30 | Janssen Pharmaceuticals Inc | Producción de bioconjugados de o18 de e. coli |
-
2021
- 2021-09-17 PE PE2023001175A patent/PE20231385A1/es unknown
- 2021-09-17 TW TW110135002A patent/TW202227128A/zh unknown
- 2021-09-17 US US17/478,584 patent/US20220088165A1/en active Pending
- 2021-09-17 MX MX2023003169A patent/MX2023003169A/es unknown
- 2021-09-17 JP JP2023517329A patent/JP7481585B2/ja active Active
- 2021-09-17 UY UY0001039428A patent/UY39428A/es unknown
- 2021-09-17 IL IL301248A patent/IL301248B2/en unknown
- 2021-09-17 AU AU2021342797A patent/AU2021342797B2/en active Active
- 2021-09-17 CN CN202180049038.6A patent/CN115803087A/zh active Pending
- 2021-09-17 EP EP21772844.3A patent/EP4213870A1/en active Pending
- 2021-09-17 IL IL308201A patent/IL308201A/en unknown
- 2021-09-17 CA CA3190820A patent/CA3190820A1/en active Pending
- 2021-09-17 KR KR1020237006127A patent/KR20230043157A/ko active Search and Examination
- 2021-09-17 BR BR112023004819A patent/BR112023004819A2/pt unknown
- 2021-09-17 WO PCT/IB2021/058485 patent/WO2022058945A1/en active Application Filing
-
2023
- 2023-02-27 CO CONC2023/0002114A patent/CO2023002114A2/es unknown
- 2023-03-15 CL CL2023000740A patent/CL2023000740A1/es unknown
- 2023-03-17 EC ECSENADI202319295A patent/ECSP23019295A/es unknown
-
2024
- 2024-04-25 JP JP2024071024A patent/JP2024099716A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023003169A (es) | 2023-03-27 |
| UY39428A (es) | 2022-03-31 |
| AU2021342797A1 (en) | 2023-02-16 |
| AU2021342797B2 (en) | 2024-02-08 |
| BR112023004819A2 (pt) | 2023-04-18 |
| IL301248B1 (en) | 2023-12-01 |
| JP7481585B2 (ja) | 2024-05-10 |
| CL2023000740A1 (es) | 2023-09-29 |
| US20220088165A1 (en) | 2022-03-24 |
| EP4213870A1 (en) | 2023-07-26 |
| IL301248B2 (en) | 2024-04-01 |
| IL301248A (en) | 2023-05-01 |
| TW202227128A (zh) | 2022-07-16 |
| CO2023002114A2 (es) | 2023-03-07 |
| IL308201A (en) | 2024-01-01 |
| WO2022058945A1 (en) | 2022-03-24 |
| JP2024099716A (ja) | 2024-07-25 |
| CA3190820A1 (en) | 2022-03-24 |
| CN115803087A (zh) | 2023-03-14 |
| JP2023539943A (ja) | 2023-09-20 |
| ECSP23019295A (es) | 2023-04-28 |
| KR20230043157A (ko) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231385A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| Hatz et al. | Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study | |
| EA202091382A1 (ru) | Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения | |
| AR100859A1 (es) | Polisacáridos y sus usos | |
| Thomsen et al. | Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model | |
| CO2019007982A2 (es) | Composiciones de neisseria meningitidis y métodos respectivos | |
| ES2495744T3 (es) | Glucanos con adyuvante | |
| CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
| CN101166559A (zh) | 包含基于聚肌苷酸-聚胞苷酸的佐剂的免疫原物质 | |
| ES2828039T3 (es) | Vacunas conjugadas de salmonela | |
| Fingermann et al. | OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves | |
| Khim et al. | Deimmunization of flagellin for repeated administration as a vaccine adjuvant | |
| ES2599908T3 (es) | Glucanos beta-1,3-enlazados conjugados | |
| ES2537019T3 (es) | Sacáridos Vi conjugados | |
| Camacho et al. | Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies | |
| Hamad | Universal fungal vaccines: could there be light at the end of the tunnel? | |
| AR123545A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| BR112022004921A2 (pt) | Composições para neisseria meningitidis e métodos das mesmas | |
| YÜKSEL MAYDA et al. | History of Epidemics and COVID-19 | |
| JP2013516396A (ja) | ロドコッカス・エクイに対する動物保護用組成物のための投与経路 | |
| WO2020084295A2 (en) | Gut bacteria derived microvesicles for vaccine delivery | |
| Abushahba et al. | Safe subunit green vaccines confer robust immunity and protection against mucosal Brucella infection in mice. Vaccines. 2023; 11: 546 | |
| PE20221442A1 (es) | Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion | |
| BR112023002872A2 (pt) | Composição de vacina que induz uma resposta imune contra o vírus sars-cov-2, procedimento para obter as omvs, e, uso da composição de vacina | |
| Senthilkumar et al. | Gateways of pathogenic bacterial entry into host cells—salmonella |